Stroke trial shows promise of UK stem cell sector
This article was originally published in Clinica
Executive Summary
The first stem cell clinical trial to receive UK approval has begun, in a patient left disabled by an ischaemic stroke (www.clinica.co.uk, 16 November 2010). If the trial is successful – and we won't know the results for some time – it will be good news not only for the patients in the trial and the company supplying the cells, but for the whole area of UK stem cell research – and biotech investors too.
You may also be interested in...
Coronavirus Notebook: UK On Cusp Of First Vaccine Approval, Moderna To File mRNA-1273 in US & EU
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Clinuvel’s Phototoxicity Drug Scenesse Approved In Third Market
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: